Paul Jones

Paul has a lifelong fascination for biology, studying genetics and gaining a PhD in molecular toxicology before embarking on a series of post-doctoral positions on a variety of receptor signalling mechanisms. On gaining an R&D position in GE Healthcare Medical Diagnostics he became a passionate born-again drug developer. For the last nine years Paul has pursued this interest at Cancer Research UK on the translation of novel small molecules, biologicals, cell therapies, imaging agents and radiotherapies into first-in-man clinical trials.